Clene Inc. Files 8-K on Sept 5, 2025

Ticker: CLNN · Form: 8-K · Filed: Sep 5, 2025 · CIK: 1822791

Clene Inc. 8-K Filing Summary
FieldDetail
CompanyClene Inc. (CLNN)
Form Type8-K
Filed DateSep 5, 2025
Risk Levellow
Pages2
Reading Time2 min
Key Dollar Amounts$0.0001, $230.00, $25,000,000, $3,706,213, $6,280,000
Sentimentneutral

Sentiment: neutral

Topics: corporate-filing, financial-reporting

TL;DR

Clene Inc. filed an 8-K on 9/5/25, check it for corporate updates.

AI Summary

Clene Inc. filed an 8-K on September 5, 2025, reporting on other events and financial statements. The company, formerly known as Chelsea Worldwide Inc., is incorporated in Delaware and has its principal executive offices in Salt Lake City, Utah.

Why It Matters

This filing provides an update on Clene Inc.'s corporate activities and financial reporting, which is important for investors to stay informed about the company's status.

Risk Assessment

Risk Level: low — This is a routine filing of an 8-K, providing standard corporate information without immediate material financial events.

Key Numbers

  • 001-39834 — SEC File Number (Identifies the company's filing with the SEC.)
  • 85-2828339 — IRS Employer Identification No. (Company's tax identification number.)

Key Players & Entities

  • Clene Inc. (company) — Registrant
  • September 5, 2025 (date) — Date of Report
  • Chelsea Worldwide Inc. (company) — Former Company Name
  • Delaware (jurisdiction) — State of Incorporation
  • Salt Lake City, Utah (location) — Principal Executive Offices

FAQ

What is the primary purpose of this 8-K filing for Clene Inc.?

The primary purpose of this 8-K filing is to report on 'Other Events' and 'Financial Statements and Exhibits' as of September 5, 2025.

When was Clene Inc. previously known by another name?

Clene Inc. was formerly known as Chelsea Worldwide Inc., with a date of name change on August 27, 2020.

Where are Clene Inc.'s principal executive offices located?

Clene Inc.'s principal executive offices are located at 6550 South Millrock Drive, Suite G50, Salt Lake City, Utah 84121.

What is the company's standard industrial classification?

Clene Inc.'s Standard Industrial Classification is 'PHARMACEUTICAL PREPARATIONS [2834]'.

What is the fiscal year end for Clene Inc.?

Clene Inc.'s fiscal year ends on December 31.

Filing Stats: 569 words · 2 min read · ~2 pages · Grade level 10.8 · Accepted 2025-09-05 16:21:26

Key Financial Figures

  • $0.0001 — nge on which registered Common Stock, $0.0001 par value CLNN The Nasdaq Capital M
  • $230.00 — rtieth of one share of Common Stock for $230.00 per share CLNNW The Nasdaq Capital
  • $25,000,000 — ng an aggregate offering price of up to $25,000,000 from time to time through the Placement
  • $3,706,213 — aggregate sales price of approximately $3,706,213 under the Equity Distribution Agreement
  • $6,280,000 — tribution Agreement for an aggregate of $6,280,000 of additional shares of Common Stock. A

Filing Documents

01 Other Events

Item 8.01 Other Events. On April 28, 2025, Clene Inc. (the "Company") entered into an equity distribution agreement (the "Equity Distribution Agreement") with Canaccord Genuity LLC as placement agent (the "Placement Agent") to offer and sell shares of its common stock, par value $0.0001 per share ("Common Stock"), having an aggregate offering price of up to $25,000,000 from time to time through the Placement Agent. Prior to the date hereof, the Company sold shares of common stock having an aggregate sales price of approximately $3,706,213 under the Equity Distribution Agreement. On September 5, 2025, the Company filed a prospectus supplement under the Equity Distribution Agreement for an aggregate of $6,280,000 of additional shares of Common Stock. A copy of the legal opinion of Holland & Knight LLP, relating to the validity of the shares in connection with the Equity Distribution Agreement is filed as Exhibit 5.1 to this Current Report on Form 8-K and is incorporated herein by reference.

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit Number Exhibit Description 5.1 Opinion of Holland & Knight LLP. 23.1 Consent of Holland & Knight LLP (contained in Exhibit 5.1). 104 Cover Page Interactive Data File (formatted as Inline XBRL). 1

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized. CLENE INC. Date: September 5, 2025 By: /s/ Robert Etherington Robert Etherington President and Chief Executive Officer 2

View Full Filing

View this 8-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.